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We have previously prepared two B7-1 transfectant clones (AC29 B7-6 and AC29 B7-7) from the AC29 murine mesothelioma (MM) cell
line which displayed markedly different in vivo growth rates and susceptibility to cytotoxic T cell killing. Using suppression subtractive
hybridisation (SSH), we searched for factors which may determine the biological distinction seen in these clones. We isolated 19 cDNA
clones from two SSH generated libraries by screening using subtracted cDNA probes and characterised them using Northern hybridisation,
sequencing, RT-PCR and real-time RT-PCR. The 19 cDNA clones comprised 16 different transcripts of which 15 were identified by
homology to known genes and one was novel. Expression of a murine endogenous retroviral (mERV) transcript mERV-AC29 was found in
the immunogenic AC29 B7-6 clone and parental AC29 but absent in AC29 B7-7. Real-time RT-PCR was used to confirm that galectin-1, the
disintegrin/metalloproteinase MDC9 and ribonucleotide reductase M1 were overexpressed in AC29 B7-7. Our results show that SSH is a
powerful method for the identification of genes expressed differentially between phenotypically different tumour cell lines or clones.
Characterisation of the role of those identified here will provide useful information in understanding genes responsible for differential
tumorigenicity.
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The changes in protein expression that are associated
with tumorigenicity are most commonly correlated with
changes in levels of specific mRNAs. We are investigating
combinations of immunomodulatory molecules for potential
use in cancer gene therapy using a murine model of
malignant mesothelioma. As part of this work, we have
previously prepared two B7-1 transfectant clones (AC29
B7-6 and AC29 B7-7) from the AC29 murine mesothelioma
cell line [1,2]. These two clones displayed markedly differ-
ing in vivo growth rates and susceptibility to cytotoxic T cell
killing. This was despite the clones expressing equivalent
levels of the B7-1 molecule and having similar in vitro
growth rates [2]. Given that these two tumour clones0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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gene expression should differ in only a few genes and that
amongst those which do differ are those which determine
the observed differences in immunogenicity and tumorige-
nicity. They do differ in their capacity to up-regulate class
II MHC expression after interferon g treatment [2] but
induction of I-Ak expression did not enhance rejection
(J.M. Marley and M.J. Garlepp, unpublished data). Identi-
fication and characterisation of differentially expressed
genes will be of value in: (a) understanding the biological
determinants associated with phenotypic differences in
cancer and (b) identifying new molecular targets for ther-
apeutic intervention.
A number of different methods have been described for
comparison of differences in gene expression. These include
subtractive hybridisation [3], differential display [4], repre-
sentational difference analysis (RDA) [5], cDNA array
hybridisation [6] and serial analysis of gene expression
(SAGE) [7]. The development of cDNA microarray technol-
ogy allows the generation of differential expression profiles
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described method of suppression subtractive hybridisation
(SSH) is similar to RDA but has a number of advantages [8].
The SSH technique allows normalisation of abundant and
rare cDNAs, subtraction of common cDNAs, isolation of
both up- and down-regulated genes and isolation of previ-
ously unknown cDNAs. The suppression PCR technique
allows selective amplification of differentially expressed
cDNAs while concurrently suppressing amplification of
those equally expressed. We have used SSH to search for
differences in gene expression which may provide clues to
the determinants of the variation in immunogenicity and
tumorigenicity seen in these B7-1 expressing clones.2. Methods
2.1. Cell lines
AC29 is a murine mesothelioma cell line developed from
asbestos-induced malignant mesothelioma (MM) in CBA/
CAH (H-2k) mice [1]. Stable B7-1 transfectant clones AC29
B7-6 and AC29 B7-7 were previously generated after stable
transfection by AC29 with the expression vector, phbApr-
neo-B7.1 [2]. AB1 and AB12 are murine mesothelioma cell
lines derived from asbestos-induced MM in Balb/c mice [1].
2.2. RNA isolation and generation of cDNA libraries using
SSH
Cell lines were grown to 80–90% confluence and mRNA
was extracted using a Poly(A)Pure Kit (Ambion, TX, USA).
Using 2 Ag of mRNA, cDNA synthesis was performed using
a PCR-Select cDNA subtraction kit (Clontech, CA, USA)
according to themanufacturer’s recommendations. Using this
cDNA, SSH was performed using the above kit and Advan-
tage cDNA polymerase mix (Clontech). By reversing the
tester and driver, two subtractive libraries were generated in
order to allow isolation of both up- and down-regulated
transcripts. The SSH-cDNA repertoire for each experiment
was cloned into the pGEM-T Easy vector (Promega, NSW,
Australia) and transformed into E. coli TOP10F (Invitrogen,
Vic., Australia).
2.3. Differential screening using subtracted probes
Clones from each library were selected and the inserts
amplified by PCR using vector primers (M13 fwd and rev)
and Taq Polymerase (Fisher-Biotec, W.A., Australia). The
PCR products were analysed, sized by gel electrophoresis,
then arrayed in duplicate by manually spotting onto nylon
membranes (Roche Biochemicals, N.S.W., Australia) and
fixed by UV cross-linking. The arrays were screened by
hybridisation using DIG (Roche Biochemicals)-labelled sub-
tracted cDNA probes which were generated from AC29 B7-6
and AC29 B7-7 SSH-cDNA by random labelling (PrimageneKit, Promega). Prior to labelling, the adapter sequences were
removed from the SSH-cDNA by digestion with RsaI and
SmaI, then purification using a QIAquick kit (Qiagen, Vic.,
Australia). Membranes were hybridised o/n at 42 jC with a
probe concentration of 2.5 ng/ml in DIG EasyHyb (Roche
Biochemicals). DIG-labelled probes were detected by chemi-
luminescence with CSPD (Roche Biochemicals). Clones
which hybridised to the forward probe alone or showed
differences in signal intensity of greater than fivefold as
assessed by densitometry were selected for further analysis.
2.4. DNA sequencing
Plasmids were prepared for sequencing by purification
using a Qiaprep Mini Plasmid Kit (Qiagen) according to the
manufacturer’s protocol. Cycle sequencing was performed in
a 10-Al reaction volume using PRISMBigDye terminator mix
(Applied Biosystems, Vic., Australia) according to the man-
ufacturer’s recommendations with 1.6 pmol of an appropriate
vector primer and 500-ng template. PTC100 hot bonnet
cyclers (MJ Research, MA, USA) were used. Following
purification by ethanol precipitation, they were analysed on
a 373A DNA Sequencer (Applied Biosystems). Sequences
were assembled and analysed using Sequencher 3.1.1 (Gene
Codes, MI, USA).
Sequence similarity searching was performed using the
BLASTN and BLASTX [9] against the non-redundant
nucleic, protein and EST databases maintained by ANGIS
(Australian National Genome Information Service, NSW,
Australia) and analysed using the program Octopus [10].
The Mouse Gene Index Database (http://www.tigr.org/tdb/
tgi) was also searched for sequence similarity [11]. Oli-
gonucleotides were designed and analysed using the pro-
gram Primer3 (http://www-genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi).
2.5. Northern analysis
Total RNA was prepared using Ultraspec (Biotecx, TX,
USA), electrophoresed in formaldehyde agarose gels, trans-
ferred by downward passive transfer (Northern Max,
Ambion) to nylon membranes (Roche Biochemicals) and
fixed by UV cross-linking. RNA loading and transfer was
assessed by fluorescent staining and photography of gels
and blots. Gene-specific DNA probes were generated by
PCR incorporating DIG-11-dUTP using cloned cDNA tem-
plates; unincorporated label was removed using a QIAquick
nucleotide removal kit (Qiagen). Membranes were hybri-
dised o/n at 50 jC with a probe concentration of 10 pM in
UltraHyb (Ambion). DIG-labelled probes were detected by
chemiluminescence with CSPD-star (Roche Biochemicals).
2.6. RT-PCR and relative RT-PCR
RT-PCR was used to analyse expression patterns. Prior to
RT-PCR, contaminating DNA was removed from the RNA
Fig. 1. Identification of differentially expressed genes by reverse screening
of SSH clones. B7-7 cDNA clones generated by SSH were arrayed onto a
nylon membrane and analysed by hybridisation (only a portion of
membrane is shown). The membrane was hybridized with a subtracted
cDNA probe generated from B7-7 (A) and B7-6 (B). Examples are
indicated of clones selected for further investigation (a), probably of similar
abundance (b) and showing background binding and therefore undeter-
mined by the technique (c).
Table 1
List of clones isolated by SSH and reverse hybridisation screening
Clonea Identity/similarity Appearance Accession no.b
7-7-6 2-hydroxyphytanoyl-coA lyase 1 AJ132139
7-7-16/25 Apo A-I binding protein 2 NM_144897
7-7-17 MDC9 1 U41765
7-7-43 Cks1 1 AB024509
7-7-48 CLCN7 1 AF063101
7-7-54 RNR-M1 1 K02927
7-7-64 COX1 1 CAA24082
7-7-65 Tim17a 1 AF106620
7-7-76 Mitofusin-2 1 AF384100
7-7-77 unknown 1 TC202094c
7-7-83/91 Galectin-1 2 X53067
7-6-7/65 Fibronectin 2 X93167
7-6-23 mitochondrial 12S RNA 1 X84382
7-6-56 mERV-AC29 1 U63133
7-6-70 HSP70 1 M19141
7-6-93 LDH-B 1 X51905
a Designates origin from AC29 B7-7 or B7-6 cells.
b Genbank accession number.
c Mouse Gene Index tentative consensus number.
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was carried out using AMV reverse transcriptase (Promega)
and 1-Ag total RNA primed with random hexamers. PCR
amplification was performed using gene-specific primers as
follows: galectin-1 forward (5V-tcaaacctggggaatgtctc-3V), re-
verse (5V-tcagcctggtcaaaggtgat-3V); Cks-1 forward (5V-gaaa-
gatggcagggagtgag-3V), reverse (5V-ccgaaaacccatctgatgtc-3V);
mitofusin-2 forward (5V-tcaggcagccactcctactt-3V), reverse (5V-
cctggctaccaagcacaact-3V); fibronectin forward (5V-ttatg-
ctcagaaccggaacg-3V), reverse (5V-caccgaataagctgtctggag-3V);
7-7-77 forward (5V-ggaccgagagcttcatgttc-3V), reverse (5V-
ttcaatggatcaaaagggatct-3V); mERV-AC29 forward (5V-cca-
gtctggcttcctgtgac-3V), reverse (5V-ttgtgggaccaaaaggacag-3V);
MDC-9 forward (5V-tgtggatttccagcttggt-3V), reverse (5V-
gtccacgcttcctccatatc-3V); RNR-M1 forward (5V-tttggatccca-
gatctcttca-3V), reverse (5V-tgggactcaatgatggcata-3V); CLCN7
forward (5V-agaggtccaacatgggtttg-3V), reverse (5V-ccggaa-
gagcttgaacactc-3V); ApoAI-BP forward (5V-tggaccaagagcttt-
ttaacg-3V), reverse (5V-gaagaggggcttgttaggtctt-3V).
Gene expression was assessed bymultiplex RT-PCR using
either h2-microglobulin or 18S primers as internal controls
for RNA quality. The h2-microglobulin primers were: for-
ward (5V-cagtagacggtcttgggctc-3V), reverse (5V-ttctctcact-gaccggcctg-3V), and the 18S primers were Quantum RNA
18S Internal Standards (Ambion). Expression levels were
assessed by relative RT-PCR using QuantumRNA 18S Inter-
nal Standards for normalisation of sample variation. The
linear range and optimal primer/competimer ratio (for 18S
primers) were determined for each gene-specific primer pair
according to the manufacturer’s recommended protocol
(Ambion). Following multiplex PCR with both gene-specific
and control primers, the products were electrophoresed in
agarose TAE gels and stained with Sybr-Gold (Molecular
Probes, OR, USA). Gel imaging and densitometry were
performed using a Kodak EDAS DC120 Imaging System.
2.7. Real-time PCR
Real-time PCR was performed using a RotorGene real-
time amplification instrument (Corbett Research, N.S.W.,
Australia) according to the manufacturer’s instructions.
Reactions were performed in a 20-Al volume with 2-
Al cDNA, 2 pmol each primer, 3.5 mM MgCl2, 200 AM
nucleotides, 1 u Taq DNA polymerase (Fisher-Biotec),
2 10 4 SYBR Green I (Molecular Probes) and 1 PCR
buffer (Fisher-Biotec). A typical protocol comprised 95 jC
for 5 min followed by 40–45 cycles of 95 jC for 20s, 55 jC
for 20s, 72 jC for 45s and 85 jC for 15s, then an additional
60s at 72 jC. Fluorescence data was acquired at 72 and
85 jC. To confirm amplification specificity, a melt curve
analysis was performed at the end of each run.
Standard curves were generated for target genes and
18S RNA using serially diluted cDNA. The threshold cycle
(CT) was determined automatically by the RotorGene
software (v4.3) using the dynamic tube normalisation set-
ting. Relative expression of the target gene was calculated
from the standard curve and normalised against the endog-
enous control 18S RNA. The results were expressed as
Fig. 2. Expression of endogenous retroviral sequence mERV-AC29 in
mouse mesothelioma cell lines. (A) Multiplex RT-PCR was performed
using primers for mERV-AC29 and h-2 microglobulin on RNA extracted
from AC29 (1), B7-6 (2), B7-7 (3), AB1 (4) and AC29 in vivo tumour
tissue (5). (B) Northern blotting of mERV-AC29 mRNA. Total RNA (5Ag/
lane) isolated from B7-6 (1) and B7-7 (2) cultures was electrophoresed and
transferred to nylon membrane. Probes were labeled with dioxygenin by
PCR, hybridized overnight at 50 jC and detected by chemiluminescence
and autoradiography. RNA loading and transfer was assessed by fluorescent
staining. 28S (4.7 kb) and 18S (1.9 kb) ribosomal RNA bands are shown.
Table 2
Expression analysis of SSH clones using relative RT-PCR
Cell line Mitofusin-2 Cks-1
AC29 2.7F 0.3 1.61F 0.0
AC29 B7-6 1.0F 0.3 1.00F 0.3
AC29 B7-7 1.0F 0.2 1.16F 0.1
AB1 2.5F 0.1 1.27F 0.2
Results are expressed as relative to AC29 B7-6.
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calibrator sample. Real-time PCR assays were conducted in
triplicate for each sample and control.
2.8. Immunoblot analysis
Cells were grown to 80–90% confluence, washed twice
with ice-cold PBS, collected by scraping and pelleted by
centrifugation. The cells were resuspended 50 mM Tris–
HCl (pH 8), 150 mM NaCl, 1% Triton X-100, 0.5%
NaDeoxycholate, 0.1% SDS with protease inhibitor Com-
pletek (Roche Biochemicals), lysed by three freeze-thaw
cycles, briefly vortexed then centrifuged at 15,000 g for
20 min at 4 jC. Protein concentrations in the supernatants
were determined using a protein assay kit (Bio-Rad, NSW,
Aust.). Proteins were resolved on 4–20% polyacrylamide
Tris–Glycine–SDS gels (iGels, Gradipore, NSW, Aust.)
and transferred to Immobilon-P PVDF membrane (Milli-
pore, Bedford, MA). Protein loading and transfer to
membranes was assessed by Coomassie or Ponceau S
staining (Sigma, NSW, Aust.). Membranes were washed
with TBS (50 mM Tris–HCl pH 7.5, 150 mM NaCl),
blocked with TBS/0.5% Tween 20 (TBST) for 1 h at room
temperature, and incubated overnight in blocking buffer
with rabbit (L. Baum, UCLA) or goat (R&D Systems,
Minneapolis, MN) polyclonal antibodies to mouse galec-
tin-1. After incubation with alkaline phosphatase conjugat-
ed secondary antibody, colour was developed using 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium
reagents (Sigma). Broad-range molecular weight markers
(Bio-Rad) were run on each gel.3. Results
3.1. Isolation and identification of differentially expressed
genes
In order to isolate potential determinants of differential
tumorigenicity, we applied SSH to mRNA isolated from
the murine mesothelioma cell clones B7-7 and B7-6. The
subtraction was performed in both directions to give both
B7-7 minus B7-6 and B7-6 minus B7-7 libraries. One
hundred cDNA clones from each library were arrayed in
duplicate by spotting onto nylon membranes and screened
by reverse hybridisation using subtracted cDNA probes.
This screening of the subtracted clones permitted ready
identification of the genes which were differentially
expressed and substantially increased the efficiency with
which clones of interest could be identified (Fig. 1). Of the
200 clones analysed, 19 (10%) were detected as overex-
pressed in one cell line with respect to the other based on
the criteria of a greater than fivefold difference in hybrid-
isation signal. Thirteen of these gave a higher signal in the
B7-7 cell line and six gave a higher signal in the B7-6
line. Many (107) cDNAs gave a positive hybridisation
signal but did not show overexpression in either cell line
and 74 gave no signal. This latter group might reasonably
be expected to include a proportion of differentially
expressed genes which were below the level of sensitivity
of the reverse hybridisation technique.
Sequencing of the 19 clones isolated demonstrated that
16 different transcripts were represented of which 15 were
provided likely identities by searching of the Genbank
database (Table 1). In some instances, homology searching
provided the identity of the clones through homology with
murine database sequences whereas in others identification
was more tentative being based on similarity to other
mammalian or eukaryotic genes as indicated in Table 1.
Significantly a number of these genes have been previous-
ly shown to be aberrantly expressed in cancer: galectin-1
[12], fibronectin [13], mdc9 [14], ribonucleotide reductase
[15] and HSP-70 [16]. Amongst the genes isolated was an
endogenous retroviral sequence (ERV) highly homologous
to a range of murine leukaemia virus (MLV) types and of
Fig. 3. Detection of galectin-1 protein in AC29 B7-1 transfectants. Protein
extracts from AC29 B7-6 and AC29 B7-7 cultures were analysed by
immunoblot using a goat anti-mouse galectin-1 antibody. Protein loading
(A) 2.5 Ag (B) 5 Ag.
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nous retroviral products have been identified as tumour
antigens [17]. This transcript was named mERV-AC29
(mERV=mouse endogenous retrovirus) and the initial
clone sequence has the Genbank accession: AY437864.
Analysis and comparison with homologous database
sequences indicated that the 7-6-56 (mERV-AC29) clone
comprised 426 bp within the open reading frame (ORF) of
the pol gene which is normally translated as part of the
gag-pol polyprotein. There were three nucleotide differ-
ences in this region compared to the melARV endogenous
retrovirus (U63133) found in the B16 murine melanoma
line, none of which gave rise to amino acid alterations.
The remaining clone (7-7-77) did not show significant
homology with functionally annotated sequences apart
from ESTs and the homologous tentative consensus (TC)
from the Mouse Gene Index database (http://www.tigr.org/
tdb/mgi/mgi.html) is given in Table 1. Three genes were
recovered twice from the SSH repertoire: galectin-1 and
ApoAI-BP from B7-7 cells, and fibronectin from B7-6
cells.
3.2. Confirmatory analysis of selected genes
A number of the SSH clones were novel at the time of
isolation and subsequently identified through new publi-
cations or database submissions by other authors. Genes
were selected for further characterisation on the basis of
novelty at the time (e.g. mERV-AC29, 7-7-77, ApoAI BP,
mitofusin) or being previously implicated in differential
tumorigenicity/immunogenicity. In order to further vali-
date the differential expression of the genes isolated, we
employed relative RT-PCR, real-time PCR and Northern
blotting. Using RT-PCR, we were able demonstrate that
the 7-6-56 (mERV-AC29) transcript was not detectable in
the B7-7 cell line but was present in B7-6, the parental
AC29 and another murine mesothelioma cell line (AB1)
(Fig. 2a). The differential abundance of the mitofusin-2
and cks-1 mRNAs was examined using relative RT-PCR
assays which did not show different expression levels in
B7-6 and B7-7 although variation was seen in these genes
between the B7-1 expressing clones and the parental
AC29 (Table 2). Relative RT-PCR proved an effective
screening assay but the establishment of each assay was
time-consuming and the technique had a limited dynamic
range.Table 3
Expression analysis of SSH clones using real-time PCR
Cell line Galectin-1 MDC9 7-7-77
AC29 6.42F 0.89 108F 13.37 198.27F 24.7
AC29 B7-6 1.00F 0.11 1.00F 0.04 1.00F 0.11
AC29 B7-7 4.81F 0.68 4.22F 0.30 2.08F 0.38
AB1 3.80F 0.46 12.85F 1.89 9.06F 1.51
AB12 2.10F 0.23 90.94F 8.41 45.90F 5.33
Results are expressed as relative to AC29 B7-6.To further streamline the validation of clones, we exam-
ined real-time RT-PCR as an alternative to relative RT-PCR.
Relative quantitation using real-time RT-PCR proved to be
more consistent and efficacious than either relative RT-PCR
or Northern blotting. Using this technique we examined the
expression of galectin-1, 7-7-77, ApoAI BP, MDC9, RNR-
M1, CLCN7, and fibronectin in B7-6, B7-7 and several
murine mesothelioma cell lines including parental AC29
(Table 3). By this technique differential expression of galec-
tin-1 was confirmed at fivefold higher in B7-7 (4.81F 0.68)
than B7-6 (1.00F 0.11). While MDC9 and RNR M1 were
also considered here as differentially expressed (approxi-
mately four- and sixfold, respectively, Table 3), lesser varia-
tions (twofold or less) were seen in ApoAI BP, CLCN7, 7-7-
77 and fibronectin. Interestingly, expression of the novel gene
7-7-77 was very substantially reduced (at least 100-fold) in
the B7-1 transfectant clones (B7-6 and B7-7) compared to the
parental AC29 and similar variations were seen inMDC9 and
RNR-M1 transcripts. Expression of fibronectin was margin-
ally higher in B7-7 (1.78F 0.10) than B7-6 (1.00F 0.11) in
contrast to expectations based upon the results of differential
screening. Immunoblot analysis of extracts from AC29 B7-6
and AC29 B7-7 cultures (Fig. 3) showed reduced galectin-1
protein the AC29 B7-6 clone consistent with SSH and real-
time PCR results.
Using Northern blotting with a 7-6-56 (mERV-AC29)
probe, a transcript of approximately 8 kb was seen in B7-6
RNA which was not observed in B7-7 RNA (Fig. 2b). This
size is consistent with other murine endogenous proviral
transcripts and its absence in B7-7 was confirmation of the
results of relative RT-PCR (Fig. 2a).4. Discussion
We have used SSH to examine differential gene expres-
sion in tumour clones, which, although originally derivedCLCN7 RNR-M1 ApoA-I BP Fibronectin
8.56F 0.76 115.77F 4.63 5.28F 0.64 10.18F 0.37
1.00F 0.12 1.00F 0.07 1.00F 0.04 1.00F 0.11
1.99F 0.11 6.27F 0.32 1.73F 0.07 1.78F 0.10
2.13F 0.06 8.21F 0.23 1.95F 0.21 1.03F 0.09
2.28F 0.14 45.31F 4.27 0.76F 0.05 0.78F 0.04
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differing tumorigenicity and immunogenicity. The identifi-
cation of molecules that define these differences may
indicate alternative strategies for cancer immunotherapy
as well as elucidating mechanisms by which tumours
escape immunotherapy. Among the repertoire of genes iso-
lated by SSH, we were able to confirm the differential ex-
pression of several and identified two, in particular, which
are worthy of further investigation: 7-6-56 (mERV-AC29)
and galectin-1.
Many endogenous retroviral (ERV) elements have been
identified in mammalian genomes and activation/expres-
sion of the gene products has been described in both
human and mouse tumours [17]. Consequently they have
been identified as potential target antigens for tumour
immunotherapy. A number of recent studies have utilised
immunotherapeutic strategies directed against endogenous
tumour antigens to develop murine models [18,19]. Al-
though as yet they have not been shown to be antigenic
targets for T-cells in human malignancies, CTL targeting
murine ERV derived epitopes have been isolated [20] and
employed in adoptive transfer studies [18]. The f8.3-kb
genome of a C-type ERV may encode several large
precursors which are processed into upwards of nine
smaller proteins. The ERV-derived gp70 protein is the
most extensively characterised retroviral derived tumour
antigen and has recently been used as an immunogen with
some success in studies in the murine colorectal carcinoma
CT26 model [21,22]. Animal models which utilise natu-
rally occurring tumour antigens are far more attractive
models for immunotherapy than those using surrogate
antigens such as OVA or beta-galactosidase. The AC29
mesothelioma model continues to be used for in vivo
investigation of anti-tumour immunotherapies [23,24] and
the identification of an endogenous retroviral transcript
will have significant implications for this model if retro-
viral antigens prove important. Certainly, retroviral anti-
gens have proved to be powerful tools in the B16
melanoma model. We hypothesize that the loss of
mERV-AC29 expression seen in the B7-7 clone may
represent loss of a principal target of the immune response
generated by expression of B7-1, thereby enabling the
clone to escape that response. Such a hypothesis is
consistent with the reduced in vitro and in vivo immuno-
genicity of B7-7 [2].
Galectin-1 is a secreted protein, whose expression is
growth- and developmentally regulated. It has been as-
cribed to both intra- and extracellular functions including
cell adhesion, regulation of cell growth and apoptosis,
neoplastic transformation and T cell immunoregulatory
activity [25,26]. Despite being the best characterised mem-
ber of the galectin family with a number of postulated
functions, the precise cellular and molecular mechanisms
of action of galectin-1 in these processes are only gradu-
ally being elucidated [27]. Up- or down-regulation of
galectin-1 expression has been observed in a number ofhuman cancers [28]; however, research in the area has
focussed almost exclusively on cell adhesion and migration
rather than immunoregulation. Given the apparent multi-
functionality of this molecule, which may differ between
tissue and cell types, it is not at all clear what effect
aberrant expression may have on tumour growth and
immunogenicity. While immunoblotting indicated differ-
ences between cellular galectin-1 protein expressions in the
tumour clones in the present study, it will be necessary to
quantitatively determine extracellular levels as well as
conduct in vivo blocking and overexpression experiments
in order to establish a role for this protein in down-
regulating anti-tumour immune responses.
Two other genes isolated by SSH in this study showed
greater than fourfold differential expression between B7-6
and B7-7: metalloproteinase MDC9 (MCMP, ADAM12)
and ribonucleotide reductase M1 (RNR M1). Both have
been previously implicated in tumour progression [14,15]
and it remains to be determined whether the four- to
sixfold differences in expression seen in these genes (and
galectin-1) are sufficient to account for the biological
differences between B7-6 and B7-7.
The efficacy of the SSH technique was ably demon-
strated by the outcome of the study. Arraying the initial
SSH clones and screening by reverse hybridisation mini-
mised the number of non-relevant clones required for
further characterisation, an important consideration for
experiments in which variation may be expected in only
a small number of genes. The high level of background
(i.e. non-differentially expressed cDNAs) seen in the SSH
repertoire generated in this study is to be expected when
closely related cell lines are compared. This is consistent
with other studies where only a few mRNA species vary
[29]. The reverse hybridisation screen used here was
limited by a manual technique, which impacted upon both
the throughput capacity and the stringency of the screen
because of variability. In the present study differential
screening was performed using subtracted probes in order
to prevent loss of rare differentially expressed transcripts.
A recognised disadvantage of this approach is that a
proportion of non-differential clones will persist after
screening and therefore verification of the clones by
another technique is critical. The effectiveness of the
screening step would be greatly enhanced by the applica-
tion of automated microarray spotting technology to pro-
vide for the analysis of larger clone numbers with greater
reproducibility, a benefit which has been explored in at
least one reported study [30]. Furthermore, the ability to
reproducibly generate duplicate arrays of SSH clones
would make screening with both subtracted and non-
subtracted probes more feasible, thereby increasing the
informativeness of the preliminary screen. The SSH tech-
nique is particularly amenable to the analysis and isolation
of oncogenes as a number of studies have demonstrated
[30,31] and its application to mRNA populations with
more complex differences such as tumour vs. normal tissue
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such as microarrays. Furthermore, SSH has an advantage
over conventional cDNA arrays in that genes not previ-
ously described may be isolated. There was a discrepancy
between SSH and real-time RT-PCR for fibronectin, which
may be a consequence of the complex alternative splicing
of this mRNA. The fibronectin SSH clones isolated here
lacked the EIIIA segment but may also cross-hybridise
with other isoforms during subtractive hybridisation. Fur-
ther investigation of fibronectin isoforms in these cells will
be required in order to clarify this issue.
As with many other methodologies for the analysis of
patterns of gene expression, the most limiting and tedious
step is the subsequent validation of the clones and, as was
found in the present study, it was important to rapidly
discriminate relevant clones from those not differentially
expressed. Although relative RT-PCR was more efficient
than Northern blotting, it still required time-consuming
development for each assay and was similarly reliant upon
densitometry, with the consequent limitations in dynamic
range and accuracy [32]. Increasingly, real-time RT-PCR
with Sybr Green I is supplanting older methods for
verification and, as far as we are aware, it has not
previously been used as an initial step to validate SSH
clones, although real-time RT-PCR with fluorescently la-
belled Taqman probes has been recently applied to further
analysis of SSH isolated genes [33,34]. Once the method-
ology is established in a laboratory, applying the technique
to a number of genes requires minimal work to establish
new assays, which is not the case for assays using
fluorescently labelled probes. In our hands, we found that
most genes could be examined using a standard set of
conditions. Furthermore, the technique is well suited to
rapid screening of numbers of genes which allow the
results of SSH to be more efficiently analysed. In this
study, we used a methodology for real-time RT-PCR which
required the generation of a standard curve for each assay.
Recently, Gentle et al. [35] have described and statistically
validated an approach which does not require the genera-
tion of standard curves in order to further streamline the
approach.
To conclude, in the present study we were able to
demonstrate the application of SSH and real-time PCR to
isolate and confirm differential gene expression between
tumour clones of differing tumorigenicity. The three genes
identified as being most up-regulated in the more aggres-
sive AC29 B7-7 clone have been previously associated
with tumour progression, so further investigation is war-
ranted to determine their relative roles in tumorigenicity.
The presence or absence of the endogenous retroviral
transcript identified in the AC29 MM cell line may have
implications for the response of specific clones to gene
immunotherapy. Further investigation is required to deter-
mine whether retroviral encoded proteins are targets of
the immune response to AC29 as is found in some other
murine tumour models.Acknowledgements
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